Form 4: Medpace Holdings CEO August J. Troendle Reports Stock Sale

August J. Troendle, CEO of Medpace Holdings, reported selling 55 shares of common stock at $400 per share on May 22, 2024.

Summary

• On May 22, 2024, August J. Troendle, the CEO of Medpace Holdings, Inc., sold 55 shares of common stock at a price of $400 per share.
• The transaction was executed through a limit order during an open window period.
• Following the transaction, Troendle directly owns 664,338 shares of Medpace Holdings, Inc.
• Troendle also indirectly owns 4,733,019 shares through Medpace Investors, LLC, where he serves as the sole manager and controlling unit holder.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a stock transaction. It doesn't inherently convey positive or negative sentiment.

Management Comments

• The transaction reported on this Form 4 was effected pursuant to a limit order placed by the Reporting Person during an open window period.
• The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ('MPI') and has sole voting and investment control with respect to the securities held by MPI.
• The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The stock sale by the CEO could be perceived neutrally or slightly negatively by shareholders, depending on their interpretation of the reasons behind the sale.

Key Dates